According to research published in the New England Journal of Medicine, triple therapy that combines either VX-659 or VX-445 with tezacaftor-ivacaftor shows promise for the treatment of adult patients with cystic fibrosis who have CFTR mutations.

[maxbutton id=”1″ url=”” text=”SUBSCRIBE TO NEWS” ]


The researchers observed significant improvement in the processing and trafficking of the Phe508del CFTR protein with VX-659-tezacaftor-ivacaftor, as well as improved chloride transport in vitro. Significant mean increases in the percentage of predicted forced expiratory volume in one second (FEV1) were seen through day 29.


A phase 2 trial found that VX-445-tezacaftor-ivacaftor improved Phe508fel CTFR protein processing, trafficking, and chloride transport in vitro to a greater extent than any two of these agents in dual combination. The treatment resulted in an increased percentage of predicted FEV1 of up to 13.8 points in the Phe508del-MF group.